TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34201806

Group type: EXPERIMENTAL
Intervention: Oral melatonin (1 mg) plus zinc (10 mg) supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 34203151

Group type: EXPERIMENTAL
Intervention: Fasting exhaled hydrogen (H2) levels
Number of subjects: 424
Study: 34204604

Group type: EXPERIMENTAL
Intervention: Specific Bioelectrical Impedance Vector Analysis (BIVA)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program
Number of subjects: 94

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 94
Study: 34205056

Group type: EXPERIMENTAL
Intervention: Experimental socks with a central discharge element
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control socks (same design, weight, and fiber without the cushioning element)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Experimental socks
Number of subjects: 38
Study: 34205106

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34205457

Group type: EXPERIMENTAL
Intervention: Core stability exercises (CSE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 34205575

Group type: EXPERIMENTAL
Intervention: Phase Angle (PhA)
Number of subjects: 94
Study: 34205660

Group type: EXPERIMENTAL
Intervention: Early collaborative intervention focusing on parent-infant interaction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34206149

Group type: EXPERIMENTAL
Intervention: DTF-QoL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EORTC QOL-C30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 0
Study: 34206446

Group type: EXPERIMENTAL
Intervention: Body-centered practices (i.e., body scan and Hatha yoga practices)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Informal practice
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Mind-centered practices (i.e., classical meditation)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Mindfulness-based interventions
Number of subjects: 104
Study: 34206826

Group type: EXPERIMENTAL
Intervention: Cantrixil (TRX-E-002-1); specific dosage and duration not mentioned.
Number of subjects: 0
Study: 34206975

Group type: EXPERIMENTAL
Intervention: Endometrial Scratching (ES) in group A1 (105 patients)
Number of subjects: 352

Group type: COMPARATOR
Intervention: No Endometrial Scratching in group B1 (104 patients)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Endometrial Scratching (ES) in group A2 (71 patients)
Number of subjects: 352

Group type: COMPARATOR
Intervention: No Endometrial Scratching in group B2 (72 patients)
Number of subjects: 352
Study: 34208053

Group type: EXPERIMENTAL
Intervention: One-on-one coaching in natural environments following a workshop
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training workshop
Number of subjects: 0
Study: 34208271

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiogram
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pulmonary lung test
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Six-minute walking test
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Serum biomarker analysis
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Number of subjects: 70
Study: 34208432

Group type: EXPERIMENTAL
Intervention: Long-term therapy with Statins and Acetyl Salicylic Acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34208859

Group type: EXPERIMENTAL
Intervention: Pilates Method
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 34209562

Group type: EXPERIMENTAL
Intervention: Adjuvant/Salvage Radiotherapy (ART/SRT)
Number of subjects: 408
Study: 34210243

Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Number of subjects: 0
Study: 34210261

Group type: EXPERIMENTAL
Intervention: Tailored training and support (T&S) program for GPs with community mobilisation in municipality 1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Tailored training and support (T&S) program for GPs without community mobilisation in municipality 2
Number of subjects: 3

Group type: COMPARATOR
Intervention: Minimal intervention to facilitate data collection in municipality 3
Number of subjects: 3
Study: 34210281

Group type: EXPERIMENTAL
Intervention: Adapted-CCI 4D-cycle caries care with non-aerosol generating procedures (non-AGP) and reduced in-office appointments' time
Number of subjects: 258
Study: 34210341

Group type: EXPERIMENTAL
Intervention: Metacognitive Remediation Therapy (MCR)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation (CCR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No cognitive-enhancing intervention
Number of subjects: 66
Study: 34210358

Group type: EXPERIMENTAL
Intervention: CFS score treated as categorical variable
Number of subjects: 7487

Group type: EXPERIMENTAL
Intervention: CFS score treated as continuous variable
Number of subjects: 7487

Group type: EXPERIMENTAL
Intervention: CFS score treated as dichotomous variable
Number of subjects: 7487

Group type: EXPERIMENTAL
Intervention: CFS score relationship with mortality
Number of subjects: 7487
Study: 34210826

Group type: EXPERIMENTAL
Intervention: SENTI-101 (a preparation of bone marrow-derived mesenchymal stromal cells engineered to express IL12 and IL21)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mSENTI-101 (murine surrogate of SENTI-101)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mSENTI-101 co-administered with checkpoint inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant cytokines (as a comparison)
Number of subjects: 0
Study: 34211280

Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Maintenance systemic corticosteroids (mSCS)
Number of subjects: 1109

Group type: COMPARATOR
Intervention: High-dosage inhaled corticosteroids with additional controllers (HD ICS+)
Number of subjects: 1109
Study: 34211773

Group type: EXPERIMENTAL
Intervention: SBRT 30 to 50 Gy in 5 fractions (median dose 40 Gy)
Number of subjects: 26
Study: 34212125

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD)
Number of subjects: 18
Study: 34212188

Group type: EXPERIMENTAL
Intervention: Cross-sectional adrenal imaging
Number of subjects: 1311
Study: 34212280

Group type: EXPERIMENTAL
Intervention: Catheter ablation with low fluoroscopy
Number of subjects: 1243
Study: 34212308

Group type: EXPERIMENTAL
Intervention: Supine position before spinal anesthesia (SA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tilted 15° position before spinal anesthesia (SA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Supine position after spinal anesthesia (SA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tilted 15° position after spinal anesthesia (SA)
Number of subjects: 20
Study: 34212476

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy
Number of subjects: 775
Study: 34212814

Group type: EXPERIMENTAL
Intervention: Delayed diagnosis, assessments and referrals
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cancellations of appointments, hospitalisations or procedures
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Home confinement-related incidents
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Inappropriate medication stopping
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Patients delayed attending or did not consult their GP due to fear of COVID-19 infection
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Patients did not consult their GP due to fear of burdening GPs
Number of subjects: 132
Study: 34212836

Group type: EXPERIMENTAL
Intervention: Improvement of dietary intakes from medium quality to very low quality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improvement of dietary intakes from medium quality to very high quality
Number of subjects: 0
Study: 34213298

Group type: COMPARATOR
Intervention: District hospitals
Number of subjects: 2983

Group type: EXPERIMENTAL
Intervention: Academic hospitals
Number of subjects: 2983
Study: 34213592

Group type: EXPERIMENTAL
Intervention: IV panitumumab
Number of subjects: 700
Study: 34213636

Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab-emtansine (T-DM1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathologic complete response (pCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing trials testing safety of omitting post-mastectomy breast and post-lumpectomy nodal irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing trials testing safety of omitting axillary lymph node dissection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) monitoring
Number of subjects: 0
Study: 34213732

Group type: EXPERIMENTAL
Intervention: 6 mg lipegfilgrastim (single SC injection)
Number of subjects: 24
Study: 34213740

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) examination
Number of subjects: 203
Study: 34213819

Group type: EXPERIMENTAL
Intervention: Ertugliflozin in E/SE Asian subjects
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: Ertugliflozin in Asian subjects from mainland China
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: Ertugliflozin in Asian subjects from the rest of the world
Number of subjects: 2276

Group type: COMPARATOR
Intervention: Control group (non-Asian subjects)
Number of subjects: 2276
Study: 34213962

Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment for memory impairment after TBI
Number of subjects: 0
Study: 34214012

Group type: EXPERIMENTAL
Intervention: Handheld Ultrasound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34214495

Group type: EXPERIMENTAL
Intervention: NSC-CRAd-S-pk7
Number of subjects: 12
Study: 34214647

Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT+)
Number of subjects: 566

Group type: COMPARATOR
Intervention: No Defibrillation Testing (DT-)
Number of subjects: 566
Study: 34215024

Group type: EXPERIMENTAL
Intervention: NTLA-2001 (0.1 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NTLA-2001 (0.3 mg/kg)
Number of subjects: 6
Study: 34215176

Group type: EXPERIMENTAL
Intervention: PAM+MI
Number of subjects: 70

Group type: COMPARATOR
Intervention: PAM
Number of subjects: 70
Study: 34215288

Group type: EXPERIMENTAL
Intervention: In-home lactation support intervention provided by International Board Certified Lactation Consultants (IBCLCs) during postpartum home visits.
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: In-home lactation support intervention
Number of subjects: 210
Study: 34215307

Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation and duration
Number of subjects: 29953

Group type: EXPERIMENTAL
Intervention: Total breastfeeding duration
Number of subjects: 29953

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 29953

Group type: EXPERIMENTAL
Intervention: Support perception during breastfeeding
Number of subjects: 29953

Group type: EXPERIMENTAL
Intervention: Desire to breastfeed longer than two months
Number of subjects: 29953

Group type: EXPERIMENTAL
Intervention: Reasons for not breastfeeding
Number of subjects: 29953
Study: 34215317

Group type: EXPERIMENTAL
Intervention: Prognostic model development using logistic regression with predictors including residual depressive symptoms, number of previous depressive episodes, co-morbid anxiety, and severity of index episode.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full model development approach including all available predictors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internal-external cross-validation for generalisability assessment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Net benefit analysis for clinical utility exploration.
Number of subjects: 0
Study: 34215319

Group type: EXPERIMENTAL
Intervention: SB cell treatment (1 × 10)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SB cell treatment
Number of subjects: 9
Study: 34215323

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment for conduct disorder (MBT-CD)
Number of subjects: 100
Study: 34215600

Group type: EXPERIMENTAL
Intervention: Clinical decision rule for identifying older adults at risk of clinically important intracranial bleeding after a fall.
Number of subjects: 0
Study: 34215614

Group type: EXPERIMENTAL
Intervention: Hyfe Cough Tracker app for monitoring night-time cough
Number of subjects: 0
Study: 34215684

Group type: EXPERIMENTAL
Intervention: Voluntary daily noise monitoring intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (matched for job title, age, gender, race, plant location, and baseline hearing level)
Number of subjects: 110
Study: 34215909

Group type: EXPERIMENTAL
Intervention: Asfotase alfa treatment
Number of subjects: 21
Study: 34216069

Group type: COMPARATOR
Intervention: CRT-D therapy
Number of subjects: 2618

Group type: COMPARATOR
Intervention: ICD implant
Number of subjects: 2618
Study: 34216189

Group type: EXPERIMENTAL
Intervention: LDL apheresis (LDL-A) for 4 weeks, 6 sessions
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Medical therapy with corticosteroids and statins
Number of subjects: 34
Study: 34216197

Group type: EXPERIMENTAL
Intervention: STOP-BANG (≥ 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: STOP-BANG (≥ 5)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Single-item analyses in OSA-positive subsample
Number of subjects: 48
Study: 34216221

Group type: EXPERIMENTAL
Intervention: CT scan findings in AII patients
Number of subjects: 48
Study: 34216247

Group type: EXPERIMENTAL
Intervention: Budigalimab 250 mg intravenously Q2W
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Budigalimab 500 mg intravenously Q4W
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Budigalimab (both dosing regimens)
Number of subjects: 81
Study: 34216598

Group type: EXPERIMENTAL
Intervention: Large-scale artificial intelligence system for polyp detection during colonoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional colonoscopy without AI assistance
Number of subjects: 0
Study: 34216757

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2524
Study: 34216825

Group type: EXPERIMENTAL
Intervention: Clinical decision support tool for infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vedolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study: 34217109

Group type: EXPERIMENTAL
Intervention: Novel effective therapies targeting key signaling pathways in PAH
Number of subjects: 0
Study: 34217304

Group type: EXPERIMENTAL
Intervention: OPTIMAT™-intervention (4-week lunch menu)
Number of subjects: 42
Study: 34217326

Group type: EXPERIMENTAL
Intervention: BREAST-Q LD questionnaire (appearance subscale)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: BREAST-Q LD questionnaire (function subscale)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: BREAST-Q LD questionnaire (both subscales)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Test-retest reliability (ICCs)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Known-group validation (patients vs normal controls)
Number of subjects: 125
Study: 34217404

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Vertical-banded gastroplasty
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Usual obesity care (Control)
Number of subjects: 2007
Study: 34217426

Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (coformulated tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg)
Number of subjects: 9709
Study: 34217773

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide
Number of subjects: 214
Study: 34217841

Group type: EXPERIMENTAL
Intervention: Multiple nerve blocks (MNB)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (CSA)
Number of subjects: 593

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 593
Study: 34217888

Group type: EXPERIMENTAL
Intervention: Modified protocol (n=37)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Original protocol (n=32)
Number of subjects: 69
Study: 34217908

Group type: EXPERIMENTAL
Intervention: Palbociclib, pembrolizumab, and letrozole
Number of subjects: 23
Study: 34218284

Group type: EXPERIMENTAL
Intervention: S antibodies
Number of subjects: 3679

Group type: EXPERIMENTAL
Intervention: N antibodies
Number of subjects: 3679
Study: 34218680

Group type: EXPERIMENTAL
Intervention: Capillary blood samples (first and second drops) taken after wiping the finger with alcohol
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Capillary blood samples (first and second drops) taken 2 hours after OGTT
Number of subjects: 109
Study: 34218718

Group type: EXPERIMENTAL
Intervention: Transcutaneous Magnetic Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34218972

Group type: EXPERIMENTAL
Intervention: Emerging diagnostics (both commercial and academic)
Number of subjects: 0
Study: 34219224

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Synsorb Pk (Shiga toxin binding agent)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Urtoxazumab (3.0 mg/kg)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Urtoxazumab (1.0 mg/kg)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 34219653

Group type: EXPERIMENTAL
Intervention: CYD-TDV dengue vaccine
Number of subjects: 0
Study: 34219663

Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 236
Study: 34220581

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 34
Study: 34221918

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 334
Study: 34221987

Group type: EXPERIMENTAL
Intervention: 12-gene Oncotype DX Breast DCIS Score
Number of subjects: 104

Group type: COMPARATOR
Intervention: Whole breast radiotherapy
Number of subjects: 104
Study: 34222013

Group type: EXPERIMENTAL
Intervention: Decitabine with a modified DHAP regimen
Number of subjects: 21
Study: 34222272

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34222294

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting 90-day survival
Number of subjects: 0
Study: 34222308

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34222435

Group type: EXPERIMENTAL
Intervention: Qingzhong (Tenofovir disoproxil fumarate)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Viread (Tenofovir disoproxil fumarate)
Number of subjects: 330
Study: 34222719

Group type: EXPERIMENTAL
Intervention: IONIS-AGT-L
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34222761

Group type: EXPERIMENTAL
Intervention: Data collection and use for decision making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaboration between health department officials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly review meetings with staff and supervisors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human resource gaps, inadequate technology infrastructure, FLW educational level, political structure, and lack of cooperation between FLWs and supervisors
Number of subjects: 0
Study: 34222765

Group type: EXPERIMENTAL
Intervention: Text messaging and Facebook groups
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Facebook content
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: HCSF2 Facebook groups
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Engagement levels
Number of subjects: 450
Study: 34222848

Group type: EXPERIMENTAL
Intervention: MVC-COV1901 5 μg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MVC-COV1901 15 μg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MVC-COV1901 25 μg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Number of subjects: 45
Study: 34222849

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate and emtricitabine (2 pills on day 1 followed by 1 pill per day on days 2-7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 34222847

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ) 600 mg BID for seven days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ)
Number of subjects: 50
Study: 34223253

Group type: EXPERIMENTAL
Intervention: Highly purified human menotropin (HP-hMG)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Recombinant follicle-stimulating hormone (FSH)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: HP-hMG
Number of subjects: 619

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 619
Study: 34223342

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity among OHCA-survivors
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Objective measure of physical activity using a hip-placed accelerometer
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Assessments of anxiety symptoms, depression symptoms, kinesiophobia, and fatigue
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity questions after one week of accelerometer use
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 6 months after OHCA
Number of subjects: 220

Group type: COMPARATOR
Intervention: Follow-up meeting for MI-controls
Number of subjects: 220
Study: 34223347

Group type: EXPERIMENTAL
Intervention: Vasopressin and Methylprednisolone (40 mg methylprednisolone and 20 IU vasopressin, with additional doses of vasopressin after each adrenaline dose for a maximum of four doses)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 492
Study: 34223356

Group type: EXPERIMENTAL
Intervention: PPV-Refresher program (psychomotor skill training using a newborn manikin with visual feedback)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 26